Immunotherapies, such as anti-PD-1 and anti-PD-L1 antibodies, offer promising new treatment options for various malignancies including non-small cell lung cancer (NSCLC). With the advent of these immunotherapies, much interest and energy has been focused on developing a companion predictive biomarker.
